Pharma News
This Week
Aug 17, 2025
Editorial | China's Biotechnology Sector Outpaces America's in Cost and Speed - The New York Times
China's biotech industry is emerging as a potential solution for rising drug costs in the U.S., offering cheaper medications for diseases like diabetes, cancer, and heart disease. Increased competition could lower prices and spur innovation. Despite challenges in healthcare access and drug development, China's significant investments in biotech aim to address its aging population and health crises.
Aug 17, 2025
Merck Shares: Consider Purchasing During Market Lows Despite Obstacles - AInvest
Merck & Co., Inc. (MRK) faces challenges due to the impending loss of exclusivity for its key drug, Keytruda, and costly acquisitions, resulting in a 15.7% underperformance this year. However, positive Phase 3 trial results for Keytruda in bladder cancer and a strong pipeline suggest potential long-term growth, making it an attractive investment opportunity for shareholders.
Aug 17, 2025
Eli Lilly's Dominance in the Obesity Market Encounters Internal and External Challenges - AInvest
Eli Lilly reported strong Q2 results for its obesity drugs Mounjaro and Zepbound, with revenues up 38% to $15.56 billion. However, its oral weight-loss pill Orforglipron underperformed in trials, raising concerns. Competitor Viking Therapeutics is developing VK-2735, a dual GLP-1/GIP agonist, which could threaten Lilly's market share with promising results in Phase 2 trials.
Aug 17, 2025
A study reveals that affluent nations spend more on vital medications, yet their financial strain is significantly less.
A new study published in JAMA Health Forum reveals that while wealthy countries pay higher list prices for essential medicines, their purchasing power results in lower overall costs. In contrast, poorer nations face a greater financial burden despite lower list prices. The study analyzed 549 essential medicines, including tenofovir disoproxil and paclitaxel, highlighting disparities in affordability across regions.
Aug 17, 2025
Eli Lilly: A Biotech Leader Transforming Long-Term Growth Strategies - AInvest
Eli Lilly (LLY) is redefining long-term value in the healthcare sector with its blockbuster drugs Mounjaro and Zepbound, which generated significant revenue in Q2 2025. The company’s robust R&D pipeline and $27 billion investment in U.S. manufacturing position it for sustained growth despite pricing pressures. LLY's strategic focus on innovation and infrastructure makes it a compelling investment opportunity.
